115 related articles for article (PubMed ID: 33135314)
41. Structure-activity relationship analysis of curcumin analogues on anti-influenza virus activity.
Ou JL; Mizushina Y; Wang SY; Chuang DY; Nadar M; Hsu WL
FEBS J; 2013 Nov; 280(22):5829-40. PubMed ID: 24034558
[TBL] [Abstract][Full Text] [Related]
42. Enhanced Inhibition of Influenza A Virus Adhesion by Di- and Trivalent Hemagglutinin Inhibitors.
Lu W; Du W; Somovilla VJ; Yu G; Haksar D; de Vries E; Boons GJ; de Vries RP; de Haan CAM; Pieters RJ
J Med Chem; 2019 Jul; 62(13):6398-6404. PubMed ID: 31251606
[TBL] [Abstract][Full Text] [Related]
43. The 2nd sialic acid-binding site of influenza A virus neuraminidase is an important determinant of the hemagglutinin-neuraminidase-receptor balance.
Du W; Guo H; Nijman VS; Doedt J; van der Vries E; van der Lee J; Li Z; Boons GJ; van Kuppeveld FJM; de Vries E; Matrosovich M; de Haan CAM
PLoS Pathog; 2019 Jun; 15(6):e1007860. PubMed ID: 31181126
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of influenza A virus infection by ginsenosides.
Dong W; Farooqui A; Leon AJ; Kelvin DJ
PLoS One; 2017; 12(2):e0171936. PubMed ID: 28187149
[TBL] [Abstract][Full Text] [Related]
45. Antiviral activity of furanocoumarins isolated from Angelica dahurica against influenza a viruses H1N1 and H9N2.
Lee BW; Ha TKQ; Cho HM; An JP; Kim SK; Kim CS; Kim E; Oh WK
J Ethnopharmacol; 2020 Sep; 259():112945. PubMed ID: 32389854
[TBL] [Abstract][Full Text] [Related]
46. Hemagglutinin Inhibitors are Potential Future Anti-Influenza Drugs for Mono- and Combination Therapies.
Sriwilaijaroen N; Suzuki Y
Methods Mol Biol; 2020; 2132():547-565. PubMed ID: 32306356
[TBL] [Abstract][Full Text] [Related]
47. Novel Polyanions Inhibiting Replication of Influenza Viruses.
Ciejka J; Milewska A; Wytrwal M; Wojarski J; Golda A; Ochman M; Nowakowska M; Szczubialka K; Pyrc K
Antimicrob Agents Chemother; 2016 Apr; 60(4):1955-66. PubMed ID: 26729490
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library.
Matsubara T; Sumi M; Kubota H; Taki T; Okahata Y; Sato T
J Med Chem; 2009 Jul; 52(14):4247-56. PubMed ID: 19558186
[TBL] [Abstract][Full Text] [Related]
49. A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities.
Lin D; Li F; Wu Q; Xie X; Wu W; Wu J; Chen Q; Liu S; He J
Sci Rep; 2016 Mar; 6():22790. PubMed ID: 26952867
[TBL] [Abstract][Full Text] [Related]
50. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.
Gubareva LV; Bethell R; Hart GJ; Murti KG; Penn CR; Webster RG
J Virol; 1996 Mar; 70(3):1818-27. PubMed ID: 8627706
[TBL] [Abstract][Full Text] [Related]
51. Catechin inhibition of influenza neuraminidase and its molecular basis with mass spectrometry.
Müller P; Downard KM
J Pharm Biomed Anal; 2015; 111():222-30. PubMed ID: 25910046
[TBL] [Abstract][Full Text] [Related]
52. Hemagglutinin-Neuraminidase Balance Influences the Virulence Phenotype of a Recombinant H5N3 Influenza A Virus Possessing a Polybasic HA0 Cleavage Site.
Diederich S; Berhane Y; Embury-Hyatt C; Hisanaga T; Handel K; Cottam-Birt C; Ranadheera C; Kobasa D; Pasick J
J Virol; 2015 Nov; 89(21):10724-34. PubMed ID: 26246579
[TBL] [Abstract][Full Text] [Related]
53. 3D-quantitative structure-activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase.
Lai Y; Yan Y; Liao S; Li Y; Ye Y; Liu N; Zhao F; Xu P
Arch Pharm Res; 2020 May; 43(5):489-502. PubMed ID: 32248350
[TBL] [Abstract][Full Text] [Related]
54. Influenza A virus surface proteins are organized to help penetrate host mucus.
Vahey MD; Fletcher DA
Elife; 2019 May; 8():. PubMed ID: 31084711
[TBL] [Abstract][Full Text] [Related]
55. Key amino acid residues of neuraminidase involved in influenza A virus entry.
Chen F; Liu T; Xu J; Huang Y; Liu S; Yang J
Pathog Dis; 2019 Aug; 77(6):. PubMed ID: 31702775
[TBL] [Abstract][Full Text] [Related]
56. A simple viral neuraminidase-based detection for high-throughput screening of viral hemagglutinin-host receptor specificity.
Sriwilaijaroen N; Suzuki Y
Methods Mol Biol; 2014; 1200():107-20. PubMed ID: 25117229
[TBL] [Abstract][Full Text] [Related]
57. Guanidinothiosialoside-Human Serum Albumin Conjugate Mimics mucin Barrier to Restrict Influenza Infection.
Yu Y; Zhou JP; Jin YH; Wang X; Shi XX; Yu P; Zhong M; Yang Y
Int J Biol Macromol; 2020 Nov; 162():84-91. PubMed ID: 32522538
[TBL] [Abstract][Full Text] [Related]
58. Antiviral potential of 3'-sialyllactose- and 6'-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses.
Günther SC; Maier JD; Vetter J; Podvalnyy N; Khanzhin N; Hennet T; Stertz S
Sci Rep; 2020 Jan; 10(1):768. PubMed ID: 31964943
[TBL] [Abstract][Full Text] [Related]
59. Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs.
Jin J; Chen S; Wang D; Chen Y; Wang Y; Guo M; Zhou C; Dou J
Biomed Pharmacother; 2018 Jan; 97():385-394. PubMed ID: 29091888
[TBL] [Abstract][Full Text] [Related]
60. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
